A clinical research group is planning a Phase II clinical trial to test the efficacy of a new monoclonal antibody, psorimab, designed to treat moderate plaque psoriasis (an autoimmune skin condition).
They select 80 participants who have been diagnosed with moderate plaque psoriasis to take part in the 12-week trial.
All of the selected participants are female, non-smokers, and are between 25 and 35 years of age.
State two other factors about the participants that the researchers should control when selecting them for this trial.
